JP4471844B2 - アミノグリコシド抗生物質を使用するprp検出方法 - Google Patents
アミノグリコシド抗生物質を使用するprp検出方法 Download PDFInfo
- Publication number
- JP4471844B2 JP4471844B2 JP2004563298A JP2004563298A JP4471844B2 JP 4471844 B2 JP4471844 B2 JP 4471844B2 JP 2004563298 A JP2004563298 A JP 2004563298A JP 2004563298 A JP2004563298 A JP 2004563298A JP 4471844 B2 JP4471844 B2 JP 4471844B2
- Authority
- JP
- Japan
- Prior art keywords
- prp
- streptomycin
- supernatant
- suspension
- homogenate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000001514 detection method Methods 0.000 title description 19
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 title 1
- 239000012530 fluid Substances 0.000 claims abstract description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 108
- 229960005322 streptomycin Drugs 0.000 claims description 54
- 239000006228 supernatant Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 108010067770 Endopeptidase K Proteins 0.000 claims description 23
- 210000004556 brain Anatomy 0.000 claims description 19
- 239000000725 suspension Substances 0.000 claims description 19
- 238000001962 electrophoresis Methods 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 13
- 241000283690 Bos taurus Species 0.000 claims description 9
- 238000013508 migration Methods 0.000 claims description 9
- 230000005012 migration Effects 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 abstract description 21
- 108091000054 Prion Proteins 0.000 abstract description 16
- 102000029797 Prion Human genes 0.000 abstract description 16
- 241001465754 Metazoa Species 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 abstract description 3
- 230000001575 pathological effect Effects 0.000 abstract description 3
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 101710138751 Major prion protein Proteins 0.000 description 59
- 239000000243 solution Substances 0.000 description 19
- 239000000523 sample Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000013060 biological fluid Substances 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 239000012472 biological sample Substances 0.000 description 7
- 230000036425 denaturation Effects 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 6
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 5
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 5
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 5
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 5
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 239000013578 denaturing buffer Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000389 anti-prion effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 208000017580 chronic wasting disease Diseases 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960002385 streptomycin sulfate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000573901 Homo sapiens Major prion protein Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- MVBJSQCJPSRKSW-UHFFFAOYSA-N n-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]prop-2-enamide Chemical compound OCC(CO)(CO)NC(=O)C=C MVBJSQCJPSRKSW-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/104998—Glucose, ketone, nitrate standard or control
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Description
a)アミノグリコシドを動物又はヒト生体に由来する、又はそれから得られた組織又は生物学的流体の懸濁液に添加し、溶液を生成し、
b)前記溶液に緩衝液を添加して、加熱し、次に得られた溶液を遠心分離し、上清から残渣を分離し、
c)電気泳動ゲル上での遊走、転移及び免疫検出後にPrPscを検出する。
a)プロテイナーゼ、例えばプロテイナーゼKを動物又はヒト生体に由来する、又はそれから得られた組織又は生物学的流体の懸濁液に添加し、
b)アミノグリコシドを前記懸濁液に添加し、
c)得られた懸濁液を緩衝液に添加して、加熱し、次に得られた溶液を遠心分離し、上清から残渣を分離し、
d)電気泳動ゲル上での遊走、転移及び免疫検出後にPrPscを検出する。
a)5%のブドウ糖溶液での動物又はヒト生体から得られた生物学的流体又は組織の均質化による10%の懸濁液の調製をし、
b)プロテイナーゼKを得られた100μlの懸濁液に添加し、次に37℃で1時間インキュベートし、
c)アミノグリコシドを懸濁液に添加し、次に37℃で2時間目にインキュベートし、
d)得られた懸濁液を緩衝液に添加して、加熱し、次に得られた溶液を遠心分離し、上清から残渣を分離し、
e)Laemmli、Nature 227(1970)、680−685によって記載されたように、Laemmliの変性緩衝液及び50%v/vの尿素8Mの溶液50μl中で残渣を懸濁する。強い渦状の攪拌後、5分間100℃で加熱し、12000gで遠心分離し、上清をSDS PAGEに対して遊走させるために、上清を回収する。
f)Laemmli、Nature 227(1970)、680−685によって記載されたように、電気泳動ゲルに対する遊走、特にドデシル硫酸ポリアクリルアミドゲル15%(SDS PAGE)に対する一次元電気泳動後、蛋白は、ニトロセルロース膜上の電気泳動によって転移し、かつアミノ酸126−160からなる特異エピトープを認識するモノクローナル抗体により、周囲温度で60分間、免疫ブロットされる。二次抗体(1/5000)は、西洋ワサビペルオキシダーゼ(IgG H+L)と結合したマウス免疫グロブリンの重及び軽鎖に向けられるヤギ抗体である。ブロットは次に洗浄され、かつ信号が、フィルム(Biomex light、Kodak)上にECLキット(Amersham)によるか、super Signal Ultra(Pierce)、及びFluor S.Multimager(BioRad)上の視覚化による化学発光で検出される。
基準技術は、1.2mlの脳ホモジェネートからのPrPsc抽出に基づく(Madec et al.、Microbial Pathogenesis、28(2000)353−362)。ホモジェネートは、100mgの脳組織当たり10μgのプロテイナーゼKにより37℃で1時間処理される前に、直径0.4mmの針を通して押し込められる。サルコシル(10%)及び10mMのトリス緩衝液(pH7.4)を添加した後、試料は、周囲温度で15分間インキュベートされ、次に10%のショ糖クッションに対し4時間20℃で245000gで遠心分離される(Beckman TL 100 ultracentrifugeuse)。最終的に残渣は、50μlのLaemmliの変性緩衝液中で溶液懸濁状態に戻し、5分間100℃で加熱し、かつ更に5分間12000gで遠心分離する。SDS PAGEに対する遊走のために、上清を回収する。
Claims (8)
- ウシの脳若しくはそのホモジェネート、又はヒトの頭脊柱液をストレプトマイシンと接触させることを特徴とするPrPscの検出方法。
- a)ストレプトマイシンをウシの脳ホモジェネート、又はヒトの頭脊柱液の懸濁液に添加し、溶液を生成し、
b)前記溶液に緩衝液を添加して、加熱し、次に得られた溶液を遠心分離し、上清から残渣を分離し、
c)電気泳動ゲル上での遊走、転移及び免疫検出後にPrPscを検出することを特徴とする請求項1に記載の方法。 - a)プロテイナーゼKをウシの脳ホモジェネート、又はヒトの頭脊柱液の懸濁液に添加し、
b)ストレプトマイシンを前記懸濁液に添加し、
c)得られた懸濁液を緩衝液に添加して、加熱し、次に得られた溶液を遠心分離し、上清から残渣を分離し、
d)電気泳動ゲル上での遊走、転移及び免疫検出後にPrPscを検出することを特徴とする請求項1に記載の方法。 - 前記ストレプトマイシンと接触させる前に、ウシの脳ホモジェネート、又はヒトの頭脊柱液をブドウ糖溶液中で均質化させることを特徴とする請求項2又は3に記載の方法。
- 加熱ステップは、60〜150℃の温度上昇に相当することを特徴とする請求項2から4のいずれか1項に記載の方法。
- ウシの脳若しくはそのホモジェネート、又はヒトの頭脊柱液中のPrPscを沈降又は検出するための薬剤であって、ストレプトマイシンを含有することを特徴とする薬剤。
- ウシの脳ホモジェネート、又はヒトの頭脊柱液中のPrPscを除去するための薬剤であって、ストレプトマイシンを含有することを特徴とする薬剤。
- ウシの脳若しくはそのホモジェネート、又はヒトの頭脊柱液中のPrPscを沈降又は検出するためのキットであって、ストレプトマイシンを含有することを特徴とするキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0216382A FR2849204B1 (fr) | 2002-12-20 | 2002-12-20 | Procede de detection de la prpsc utilisant un antibiotique d de la famille des aminoglycosides pour l'elimination et la detection de la prpsc dans des echantillons biologiques |
PCT/FR2003/003856 WO2004059321A1 (fr) | 2002-12-20 | 2003-12-19 | Procede de detection de la prp utilisant un antibiotique des aminoglycosides |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006510913A JP2006510913A (ja) | 2006-03-30 |
JP4471844B2 true JP4471844B2 (ja) | 2010-06-02 |
Family
ID=32406304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004563298A Expired - Lifetime JP4471844B2 (ja) | 2002-12-20 | 2003-12-19 | アミノグリコシド抗生物質を使用するprp検出方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7695918B2 (ja) |
EP (1) | EP1573336B1 (ja) |
JP (1) | JP4471844B2 (ja) |
CN (1) | CN1729396A (ja) |
AT (1) | ATE423321T1 (ja) |
AU (1) | AU2003299389A1 (ja) |
BR (1) | BR0317224A (ja) |
DE (1) | DE60326269D1 (ja) |
ES (1) | ES2322704T3 (ja) |
FR (1) | FR2849204B1 (ja) |
MX (1) | MXPA05006765A (ja) |
WO (1) | WO2004059321A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2865280B1 (fr) * | 2004-01-20 | 2007-01-12 | Biomerieux Sa | Procede de detection de la prp utilisant une molecule ayant au moins une charge positive et/ou au moins une liaison osidique et un ligand autre qu'un ligand proteique |
FR2888937B1 (fr) | 2005-07-21 | 2012-10-26 | Biomerieux Sa | Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes |
US7325983B1 (en) * | 2006-08-25 | 2008-02-05 | Emcore Corporation | 10GBASE-LX4 optical transceiver in XFP package |
KR102120069B1 (ko) * | 2011-11-21 | 2020-06-08 | 이노베이션 해머 엘엘씨 | 실리케이트계 기질을 사용하여 식물을 성장시키는 방법 및 시스템, 내생성 글리코피라노실-단백질 유도체를 위한 외생성 글리코피라노사이드 사용에 의한 향상된 광합성 생산성 및 광안전화 재배, 및 그를 위한 제제, 방법 및 시스템 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993544A (en) * | 1975-01-20 | 1976-11-23 | Massachusetts Institute Of Technology | Derivatives of streptomycin and method of producing streptomycin derivatives by mutational biosynthesis |
US6221614B1 (en) * | 1997-02-21 | 2001-04-24 | The Regents Of The University Of California | Removal of prions from blood, plasma and other liquids |
EP0861900A1 (en) * | 1997-02-21 | 1998-09-02 | Erziehungsdirektion Of The Canton Zurich | Immunological detection of prions |
US6322802B1 (en) * | 1999-06-01 | 2001-11-27 | The Regents Of The University Of California | Method of sterilizing |
EP0980438A4 (en) | 1997-05-02 | 2004-10-27 | Integrated Res Technology Llc | BETAINE AS AID FOR SENSITIVITY TESTING AND ANTIMICROBIAL THERAPY |
CA2385743A1 (en) * | 1999-09-28 | 2001-04-05 | Universitat Zurich | Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
IL150925A0 (en) | 2000-02-01 | 2003-02-12 | Little Inc A | Chemical and/or biological decontamination system |
IL141950A0 (en) * | 2000-10-22 | 2002-03-10 | Hadasit Med Res Service | Diagnosis of prion diseases |
DE10119713A1 (de) * | 2001-04-21 | 2002-10-24 | Prionics Ag Zuerich | Verfahren zur Untersuchung von Prion-Protein enthaltenden Proben auf das eventuelle Vorliegen der PrPSc-Form |
FR2865280B1 (fr) * | 2004-01-20 | 2007-01-12 | Biomerieux Sa | Procede de detection de la prp utilisant une molecule ayant au moins une charge positive et/ou au moins une liaison osidique et un ligand autre qu'un ligand proteique |
US20150041230A1 (en) | 2013-08-12 | 2015-02-12 | GKart Inc. | Amusement vehicle, amusement environment for a vehicle and method of using the same |
-
2002
- 2002-12-20 FR FR0216382A patent/FR2849204B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-19 AU AU2003299389A patent/AU2003299389A1/en not_active Abandoned
- 2003-12-19 CN CNA2003801067738A patent/CN1729396A/zh active Pending
- 2003-12-19 WO PCT/FR2003/003856 patent/WO2004059321A1/fr active Application Filing
- 2003-12-19 EP EP03799681A patent/EP1573336B1/fr not_active Expired - Lifetime
- 2003-12-19 JP JP2004563298A patent/JP4471844B2/ja not_active Expired - Lifetime
- 2003-12-19 AT AT03799681T patent/ATE423321T1/de not_active IP Right Cessation
- 2003-12-19 ES ES03799681T patent/ES2322704T3/es not_active Expired - Lifetime
- 2003-12-19 MX MXPA05006765A patent/MXPA05006765A/es active IP Right Grant
- 2003-12-19 BR BR0317224-4A patent/BR0317224A/pt not_active IP Right Cessation
- 2003-12-19 DE DE60326269T patent/DE60326269D1/de not_active Expired - Lifetime
-
2005
- 2005-06-13 US US11/151,066 patent/US7695918B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1573336A1 (fr) | 2005-09-14 |
JP2006510913A (ja) | 2006-03-30 |
DE60326269D1 (de) | 2009-04-02 |
ES2322704T3 (es) | 2009-06-25 |
WO2004059321A1 (fr) | 2004-07-15 |
FR2849204A1 (fr) | 2004-06-25 |
CN1729396A (zh) | 2006-02-01 |
AU2003299389A8 (en) | 2004-07-22 |
MXPA05006765A (es) | 2006-02-17 |
US20060014215A1 (en) | 2006-01-19 |
ATE423321T1 (de) | 2009-03-15 |
FR2849204B1 (fr) | 2005-02-11 |
AU2003299389A1 (en) | 2004-07-22 |
WO2004059321A8 (fr) | 2005-06-30 |
BR0317224A (pt) | 2005-11-01 |
EP1573336B1 (fr) | 2009-02-18 |
US7695918B2 (en) | 2010-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101941308B1 (ko) | 장, 혈액-뇌 장벽 투과성 검출 방법 및 테스트 물질 | |
US20160077110A1 (en) | Detection of Misfolded Amyloid Beta Protein | |
CN109738653B (zh) | 用于阿尔茨海默症的检测、诊断或风险预测的抗原蛋白组合以及包含其的试剂盒 | |
BR102017026619A2 (pt) | ensaio melhorado para a diagnose de alergia a amendoim | |
JP2010271078A (ja) | 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法 | |
JP4471844B2 (ja) | アミノグリコシド抗生物質を使用するprp検出方法 | |
US6132977A (en) | Measurement of a CNS protein in cerebrospinal or amniotic fluid | |
CN107525919A (zh) | 诊断共孵育测定法 | |
US20060166283A1 (en) | Means for detecting neurodegenerative processes and applications of same | |
AU2013285362B2 (en) | Tropomyosin isoforms related to Alzheimers disease and Mild Cognitive Impairment | |
CN113985035A (zh) | 趋化因子ccl28作为标志物在制备干燥综合征诊断试剂中的应用 | |
RU2523413C1 (ru) | СПОСОБ ДИАГНОСТИКИ РЕВМАТОИДНОГО АРТИРИТА ПО НАЛИЧИЮ АНТИТЕЛ К МОДИФИЦИРОВАННОМУ ЦИНТРУЛЛИНИРОВАННОМУ ВИМЕНТИНУ (Anti-MCV) В РОТОВОЙ ЖИДКОСТИ | |
JPWO2020162388A1 (ja) | パーキンソン病と多系統萎縮症との判別方法および判別キット | |
EP3417295B1 (en) | Method for the diagnosis and typing of amyloidosis | |
US20070092919A1 (en) | Monitoring of liquids for disease-associated materials | |
JP2016527509A (ja) | 牛乳中のタンパク質に対するアレルギーの治療のための経口免疫療法の有効性の予測方法 | |
JP2010281725A (ja) | ラクトフェリンの催炎性フラグメントの測定方法 | |
JP2015503106A (ja) | テネイシンcおよび関節リウマチにおけるその使用 | |
US20110117583A1 (en) | Method for detecting the existence of renal calculi and/or inflammation of the excretory urinary tracts | |
JPH0625298A (ja) | 多包虫由来の抗原並びにそれを用いた診断用試薬及び診断方法 | |
JP4264469B2 (ja) | 痴呆症の検査方法 | |
CN111537744B (zh) | 一种基于乳脂肪球膜特性的乳凝集素或粘蛋白1的elisa定量检测方法 | |
JP6347459B2 (ja) | ミルクアレルギー個体の属性の予測方法 | |
BRPI0711096A2 (pt) | identificação de proteìnas de prion no leite | |
Abbas et al. | The Diagnostic Role of Anti-Human Salivary Gland Protein-1 (anti-SP1) in the Early Detection of Primary Sjogren’s Syndrome in Some Iraqi Patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060928 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090513 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090529 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090820 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090929 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100121 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100219 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100302 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130312 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |